IP Library Granted Patent US 9,937,166
Granted Patent B2
US 9,937,166 · App. 15/348,253 · Granted Apr 10, 2018

Use of levocetirizine and montelukast in the treatment of traumatic injury

Inventor: Bruce Chandler May (Santa Barbara, CA)
Assignee: Inflammatory Response Research, Inc.
A61K31/495A61K31/407A61K31/424A61K31/43A61K31/431A61K31/47A61K31/496A61K31/505A61K31/5383A61K31/546A61K31/635A61K31/65A61K31/7052A61K31/7056A61K38/14A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,937,166
App. No.
15/348,253
Granted
Apr 10, 2018
Kind
B2
Abstract

The embodiments described herein include methods and formulations for treating lung and brain injury. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.

Claims (11)

1. A method of treating traumatic lung injury or a symptom of traumatic lung injury in a patient in need thereof comprising administering an effective amount of a combination of levocetirizine and montelukast wherein the traumatic lung injury is a lung contusion.

2. The method of claim 1 , wherein the traumatic lung injury is the result of a primary injury during a traumatic event resulting in physical damage.

3. The method of claim 1 , wherein the combination is administered at the onset of symptoms.

4. The method of claim 1 , wherein the combination is administered at the time of diagnosis.

5. The method of claim 1 , wherein the combination is administered in a sequential manner.

6. The method of claim 1 , wherein the combination is administered in a substantially simultaneous manner.

7. The method of claim 1 , further comprising the administration of an additional active agent.

8. The method of claim 7 , wherein the additional active agent is selected from the group consisting of an antibiotic, antiviral, anti-parasitic, antifungal, vasopressor, diuretic, anticoagulant, anti-seizure medication, proton pump inhibitor, H2 receptor antagonist, antipyretic agent, anti-inflammatory drug, anti-neoplastic drug, and combinations thereof.

9. The method of claim 8 , wherein the additional active agent is an antibiotic selected from the group consisting of vancomycin, meropenem, amoxicillin/beta clauvulanic acid, levofloxacin, piperacillin/tazobactam, ceftriaxone, clindamycin, azithromycin, trimethoprim/sulfamethoxazole, doxycycline or combinations thereof.

10. The method of claim 1 , wherein the combination is administered to the patient by one or more of the routes consisting of enteral, intravenous, intraperitoneal, inhalation, intramuscular, subcutaneous and oral.

11. The method of claim 1 , wherein the levocetirizine and montelukast are administered by the same route.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2018
From: MAY, BRUCE CHANDLER
To: IRR, INC.
Reel/Frame 047724/0470 →
Continuity (4)
Continuation 14831469 · Aug 20, 2015
Continuation PCTUS2014021706 · Mar 7, 2014
Provisional Application 61780336 · Mar 13, 2013
Related Publication 20170056395A1 · Mar 2, 2017